Walter Rosebrough Jr Purchases 7,000 Shares of Cooper Companies (NASDAQ:COO) Stock

The Cooper Companies, Inc. (NASDAQ:COO) Director Walter Rosebrough, Jr. purchased 7,000 shares of Cooper Companies stock in a transaction that occurred on Friday, September 11th. The shares were acquired at an average price of $54.11 per share, with a total value of $378,770.00. Following the acquisition, the director directly owned 17,000 shares of the company’s stock, valued at $919,870. This trade represents a 70.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Cooper Companies Stock Performance

NASDAQ:COO traded down $0.95 on Tuesday, hitting $53.27. The company’s stock had a trading volume of 4,408,999 shares, compared to its average volume of 2,501,526. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23. The stock has a fifty day moving average of $71.25 and a two-hundred day moving average of $69.40. The firm has a market capitalization of $10.13 billion, a P/E ratio of 18.18, a price-to-earnings-growth ratio of 2.19 and a beta of 0.82. The Cooper Companies, Inc. has a one year low of $51.01 and a one year high of $89.83.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.10 billion. During the same period last year, the firm posted $0.49 earnings per share. The business’s revenue was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Research analysts predict that The Cooper Companies, Inc. will post 4.53 earnings per share for the current year.

Cooper Companies declared that its board has approved a share buyback program on Wednesday, September 9th that authorizes the company to buyback $3.00 billion in shares. This buyback authorization authorizes the medical device company to purchase up to 22.7% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Institutional Investors Weigh In On Cooper Companies

A number of hedge funds and other institutional investors have recently modified their holdings of COO. Root Financial Partners LLC increased its position in Cooper Companies by 104.5% during the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after acquiring an additional 162 shares during the period. Avalon Trust Co bought a new stake in Cooper Companies in the 2nd quarter valued at about $25,000. SJS Investment Consulting Inc. boosted its holdings in Cooper Companies by 107.5% in the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 187 shares during the period. Elevation Wealth Partners LLC grew its position in shares of Cooper Companies by 1,136.4% during the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock worth $29,000 after purchasing an additional 375 shares in the last quarter. Finally, Continuum Advisory LLC acquired a new position in shares of Cooper Companies during the 2nd quarter worth approximately $30,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Cooper Companies in a research note on Friday, September 4th. Piper Sandler lowered shares of Cooper Companies from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $86.00 to $59.00 in a research note on Thursday, September 10th. KeyCorp reissued a “sector weight” rating on shares of Cooper Companies in a report on Friday, June 5th. BNP Paribas Exane lowered their price target on shares of Cooper Companies from $95.00 to $92.00 and set an “outperform” rating on the stock in a report on Monday, June 8th. Finally, Stifel Nicolaus set a $70.00 price objective on shares of Cooper Companies and gave the stock a “buy” rating in a research report on Thursday, September 10th. Five research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $71.47.

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.